Tolametinib (HL-085/Keluping®)
NRAS-mutant Advanced Melanoma (post-PD-1/PD-L1 failure)
ApprovedCommercial
Key Facts
Indication
NRAS-mutant Advanced Melanoma (post-PD-1/PD-L1 failure)
Phase
Approved
Status
Commercial
Company
About KeChow Pharma
A clinical-stage Chinese biotech developing novel, best-in-class small molecule drugs for oncology, with its first NMPA-approved MEK inhibitor for NRAS-mutant melanoma.
View full company profile